Who owns RECURSION PHARMACEUTICALS, INC.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of RXRX from SEC Form 13F filings across 343 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 343 institutions disclosed 361.9M shares of RECURSION PHARMACEUTICALS, INC. worth $1.33B — about 68% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
343
13F holders
$1.33B
value, 2026 filers
68%
of shares outstanding (361.9M sh)
53
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of RXRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 50.3M | $184.6M | 0.0% | 9.4% | +16.5% |
| 2 | ARK Investment Management LLC | 41.3M | $151.7M | 1.0% | 7.8% | +2.8% |
| 3 | STATE STREET CORP | 34.7M | $127.4M | 0.0% | 6.5% | +21.8% |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 31.1M | $114.3M | 0.0% | 5.8% | +36.8% |
| 5 | BAILLIE GIFFORD & CO | 23.5M | $86.2M | 0.1% | 4.4% | -0.8% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 22.8M | $83.6M | 0.0% | 4.3% | +2.3% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 13.8M | $50.7M | 0.0% | 2.6% | +12.6% |
| 8 | SOFTBANK GROUP CORP. | 13.6M | $50.0M | 0.3% | 2.6% | 0.0% |
| 9 | MIC Capital Management UK LLP | 9.6M | $35.4M | 9.0% | 1.8% | 0.0% |
| 10 | UBS Group AG | 8.9M | $32.8M | 0.0% | 1.7% | +75.4% |
| 11 | NORGES BANKNEW | 6.8M | $25.1M | 0.0% | 1.3% | new |
| 12 | Data Collective IV GP, LLC | 5.9M | $21.8M | 27.8% | 1.1% | 0.0% |
| 13 | Sumitomo Mitsui Trust Group, Inc. | 5.5M | $20.2M | 0.0% | 1% | +1.7% |
| 14 | Amova Asset Management Americas, Inc. | 5.5M | $20.2M | 0.3% | 1% | +1.7% |
| 15 | NORTHERN TRUST CORP | 4.8M | $17.5M | 0.0% | 0.9% | +19.9% |
| 16 | MARSHALL WACE, LLP | 4.7M | $17.3M | 0.0% | 0.9% | +63.9% |
| 17 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4.1M | $15.2M | 0.0% | 0.8% | +8.7% |
| 18 | DCVC Opportunity Fund II GP, LLC | 4.0M | $14.5M | 84.3% | 0.7% | 0.0% |
| 19 | GOLDMAN SACHS GROUP INC | 3.9M | $14.4M | 0.0% | 0.7% | -35.4% |
| 20 | VANGUARD FIDUCIARY TRUST CO | 3.5M | $12.7M | 0.0% | 0.7% | -1.3% |
| 21 | TWO SIGMA INVESTMENTS, LP | 3.4M | $12.3M | 0.0% | 0.6% | -17.5% |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 3.3M | $12.1M | 0.0% | 0.6% | -22.1% |
| 23 | FIRST TRUST ADVISORS LP | 3.0M | $11.2M | 0.0% | 0.6% | +16.5% |
| 24 | MORGAN STANLEY | 2.7M | $10.1M | 0.0% | 0.5% | +25.5% |
| 25 | IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 2.6M | $9.6M | 0.6% | 0.5% | +1.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.